Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2026 16:30 ET | Source: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
June 03, 2026 16:30 ET | Source: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 03 juin 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...
June 02, 2026 11:23 ET | Source: Exousia Pro, Inc.

NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization

NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
June 01, 2026 16:10 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today...
May 28, 2026 05:22 ET | Source: InnoCare Pharma

InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.
May 27, 2026 17:02 ET | Source: kneat.com, inc.

Kneat Announces Results of Voting at Annual General Meeting

Kneat shareholders elect board of directors, approve auditors at Kneat's Annual General Meeting today
May 27, 2026 06:02 ET | Source: InnoCare Pharma

InnoCare Announces Approval of Orelabrutinib in Australia

Orelabrutinib (HIBRUKA®) has been approved by TGA in Australia, offering a new treatment option for patients with R/R MCL in the region.
May 26, 2026 00:30 ET | Source: Custom Market Insights

[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, May 26, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Bioprocess Automation Software Market Size, Trends and Insights By Type...
May 22, 2026 08:00 ET | Source: InnoCare Pharma

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.
May 20, 2026 07:00 ET | Source: Envetec

Envetec Receives Massachusetts Approval for GENERATIONS® Medical and Biological Waste Treatment Technology

Envetec approval creates new alternative to centralized medical waste treatment in Massachusetts.